✦ LIBER ✦

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

✍ Scribed by Salazar, Fernanda; Molina, Miguel Angel; Sanchez-Ronco, Maria; Moran, Teresa; Ramirez, Jose Luis; Sanchez, Jose Miguel; Stahel, Rolf; Garrido, Pilar; Cobo, Manuel; Isla, Dolores; Bertran-Alamillo, Jordi; Massuti, Bartomeu; Cardenal, Felipe; Manegold, Christian; Lianes, Pilar; Trigo, Jose Manuel; Sanchez, Jose Javier; Taron, Miquel; Rosell, Rafael

Book ID: 119320432
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 405 KB
Volume: 72
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2010.07.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prospective, multicenter, randomized, in

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

✍ Heigener, David F.; von Pawel, Joachim; Eschbach, Corinna; Brune, Andreas; Schmi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 316 KB